GlycArt biotechnology AG. GLYCART’s mission is to become an antibody power-house within the Roche Group developing a new generation of antibody products with increased efficacy that address unmet clinical needs. GLYCART’s core platform technology – GlycoMAb® – enhances the power of monoclonal antibodies.On July 19, 2005 Roche announced that it has acquired GLYCART to strengthen its expertise in therapeutic antibody research. The acquisition was completed on July 26, 2005.Committed to create a balanced and diversified product portfolio, we have developed an integrated set of technologies to allow a faster development of our candidate compounds.GlycoMAb® provides the Company with a unique competitive advantage for developing highly potent antibodies for carefully selected targets. GLYCART’s proprietary pipeline is composed of three different, GlycoMAb®-modified antibodies at the preclinical development stage. In addition, two candidates are undergoing lead optimization. All antibodies are humanized in-house.Roche acquires Swiss based GlycArt Biotechnology to strengthen expertise in therapeutic antibody research